Mon, May 12, 10:21 AM (40 days ago)
**Universal Biosensors, Inc. (UBI, UBI:ASX) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** A$1,554,659 (up 6% YoY) - Products: A$1,329,813 (stable YoY) - Services: A$224,846 (down 22% YoY) - **Gross Profit:** A$843,344 (stable YoY) - **Net Loss:** A$3,837,950 (up 11% YoY) - **Cash Flow:** A$3,719,264 used in operations (down 35% YoY) - **Cash Position:** A$4,916,315 (down 33% YoY) **Profit Margins:** - Gross Margin: 54% (stable YoY) - Operating Margin: -280% (down from -249% YoY) **Earnings Changes:** - Basic and Diluted Net Loss per Share: A$0.01 (down from A$0.02 YoY) **Trends & Uncertainties:** - Revenue growth driven by Sentia and Petrackr products. - Increased R&D expenses (up 213% YoY) due to new product development. - Going concern raised due to insufficient cash to fund operations beyond Q3 2025. - Management plans to raise additional capital and grow revenue. **Future Operations Impact:** - Launch of AQUASCOUT water testing platform in H2 2025. - Continued investment in R&D and commercialization efforts. - Potential delays or issues in commercialization may require adjustments to operating expenditure. **Key Metrics:** - Current Ratio: 2.99 (down from 3.96 YoY) - Shareholders' Equity per Share: A$0.05 (down from A$0.08 YoY) **Management's Outlook:** - Focus on increasing commercialization efforts and reducing R&D expenditure. - Monitor cash position and adjust operating expenditure as needed. - Explore options for additional funding to ensure continuity as a going concern.